Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - RAPT Therapeutics

Next Previous
Drug Profile

Research programme: small molecule therapeutics - RAPT Therapeutics

Alternative Names: CCR4 inhibitors - RAPT Therapeutics; GCN2 inhibitors - RAPT Therapeutics; GCN2 program - RAPT Theraperutics; HPK1 Inhibitors - RAPT Therapeutics; MDSC inhibitors - RAPT Theraperutics; Myeloid-derived suppressor cell inhibitors - RAPT Therapeutics; Regulatory T-cell inhibitors - RAPT Therapeutics; USP7 inhibitors - RAPT Therpaeutics

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FLX Bio
  • Developer RAPT Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action CCR4 receptor antagonists; EIF2AK4 protein inhibitors; Hematopoietic progenitor kinase 1 inhibitors; Regulatory T-lymphocyte inhibitors; USP7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 May 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
  • 11 Nov 2024 RAPT Therapeutics plans to identify a new candidate for Inflammatory diseases by mid-2025
  • 28 Mar 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top